Lung Cancer Trial Results
- Denosumab Effective for Multiple Myeloma and Solid Tumors
(Posted: 06/08/2011) - Results from a randomized phase III trial of denosumab to prevent skeletal related events in several types of cancer were published online February 22, 2011, in the Journal of Clinical Oncology (JCO).
- When Combined with Chemotherapy, Bevacizumab Is Associated with Increased Risk of Death
(Posted: 03/30/2011) - Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was published February 2, 2011, in JAMA.
- Can Aspirin Reduce Cancer Risk and Mortality?
(Posted: 03/30/2011) - A meta-analysis of eight clinical trials involving regular aspirin use showed a substantial reduction in mortality for a number of different cancers.
- Cetuximab Plus Chemotherapy Extends Survival for Advanced Lung Cancer
(Posted: 12/29/2010) - Patients with advanced non-small-cell lung cancer (NSCLC) who received cetuximab (Erbitux) plus chemotherapy lived on average 5 weeks longer than patients who received chemotherapy alone, according to results of a randomized phase III trial.
- Crizotinib Continues to Show Promise for Some Lung Tumors, Faces Challenge of Drug Resistance
(Posted: 12/07/2010) - New data from a phase I trial of crizotinib, a small-molecule drug that targets cancer-causing chromosomal rearrangements involving the gene ALK, in patients with non-small cell lung cancer add to positive results published October 28, 2010, in the New England Journal of Medicine.